Department of Biochemistry, Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram, Kerala, India.
Immunol Invest. 2013;42(4):324-40. doi: 10.3109/08820139.2013.764316.
Anti-α-galactoside antibody (anti-Gal) from human plasma that bound to α-galactoside-bearing guar galactomannan gel and was eluted with specific sugar (affinity-purified anti-Gal ; APAG) invariably contained apo(a) and apo B subunits in a proportion close to that in plasma lipoprotein(a) [Lp(a)]. Since LDL does not contain apo(a), result suggested Lp(a) as a component of APAG. Lp(a) in APAG was complexed with anti-Gal since plate-coated anti-apo(a) captured Lp(a) along with the antibody. Association of Lp(a) with anti-Gal in APAG was considerably lower in presence of anti-Gal-specific sugar, suggesting that Lp(a) occupied the sugar-binding site of anti-Gal. Content of Lp(a)-bound anti-Gal in APAG, though a minor fraction of total antibody, increased steadily with total Lp(a) content of plasma. Further, Lp(a) released from immune complex-rich fraction of plasma by anti-Gal- specific sugar was proportional to total plasma Lp(a). Anti-Gal titre decreased with increasing Lp(a) concentration among 114 plasma samples. Results indicate the potential of anti-Gal molecules with its binding site partially occupied by Lp(a) molecule(s) to a) use the remaining binding site(s) to recognize other macromolecules or cells and b) transport Lp(a) across Fc receptor-bearing cells.
来自人血浆的抗α-半乳糖苷抗体(抗-Gal)与含有α-半乳糖苷的瓜尔半乳甘露聚糖凝胶结合,并使用特定的糖洗脱(亲和纯化的抗-Gal;APAG),始终在与血浆脂蛋白(a)[Lp(a)]接近的比例中包含载脂蛋白(a)和载脂蛋白 B 亚基。由于 LDL 不含载脂蛋白(a),因此结果表明 Lp(a)是 APAG 的组成部分。APAG 中的 Lp(a)与抗-Gal 复合,因为板涂层抗-载脂蛋白(a)与抗体一起捕获 Lp(a)。在存在抗-Gal 特异性糖的情况下,APAG 中 Lp(a)与抗-Gal 的结合显著降低,表明 Lp(a)占据了抗-Gal 的糖结合位点。APAG 中与 Lp(a)结合的抗-Gal 尽管是总抗体的一小部分,但随着血浆中总 Lp(a)含量的增加而稳定增加。此外,通过抗-Gal 特异性糖从富含免疫复合物的血浆部分释放的 Lp(a)与总血浆 Lp(a)成正比。在 114 个血浆样本中,抗-Gal 效价随着 Lp(a)浓度的增加而降低。结果表明,具有部分被 Lp(a)分子占据的结合位点的抗-Gal 分子有潜力 a)使用剩余的结合位点识别其他大分子或细胞,b)将 Lp(a)转运穿过 Fc 受体结合细胞。